| |
n/N (%) [n]
|
|---|
|
Treatment
|
Low risk
|
Intermediate risk
|
High risk
|
|---|
|
Temsirolimus 175/75 mg
|
9/12 (75)
|
11/18 (61)
|
8/10 (80)
|
|
[5 PR, 4 SD]
|
[1 CR, 5 PR, 5 SD]
|
[1 PR, 7 SD]
|
|
Temsirolimus 175/25 mg
|
10/13 (77)
|
5/15 (33)
|
5/15 (33)
|
|
[2 PR, 8 SD]
|
[1 PR, 4 SD]
|
[5 SD]
|
|
INV therapy
|
4/11 (36)
|
8/20 (40)
|
0/9 (0)
|
|
[4 SD]
|
[1 CR, 7 SD]
| |
- *Disease assessment was based on radiographic review by independent radiologists and review of clinical data by independent oncologists; evaluable patients were those with tumor assessment available.
- MIPI = Mantle Cell Lymphoma International Prognostic Index; PR = partial response; SD = stable disease ≥8 weeks; CR = complete response; INV = Investigator’s choice.
